2005
DOI: 10.1097/01.hjr.0000176513.07037.83
|View full text |Cite
|
Sign up to set email alerts
|

Cardiac isoform of alpha-2 macroglobulin as a novel diagnostic marker for cardiac diseases

Abstract: Levels of CA2M in cardiac diseases were significantly higher than other sample groups but moderately elevated in leprosy. This protein could be considered for diagnosis of cardiac diseases as a serum marker.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

1
4
0

Year Published

2007
2007
2023
2023

Publication Types

Select...
5
1

Relationship

0
6

Authors

Journals

citations
Cited by 11 publications
(5 citation statements)
references
References 9 publications
1
4
0
Order By: Relevance
“…Earlier studies showed that cardiac isoform of alpha 2 macroglobulin (CA2M), is a high molecular weight serum protein (182000Mr), involved in development of cardiac hypertrophy in rats [5]. Further, our studies confirmed that CA2M could be used as a diagnostic marker for cardiac disease [6], cardiac manifestations in HIV/AIDS and diabetic patients [7,8]. Since it is a novel area of research, further studies are required to confirm the clinical utility of CA2M in HIV patients.…”
Section: Introductionsupporting
confidence: 85%
“…Earlier studies showed that cardiac isoform of alpha 2 macroglobulin (CA2M), is a high molecular weight serum protein (182000Mr), involved in development of cardiac hypertrophy in rats [5]. Further, our studies confirmed that CA2M could be used as a diagnostic marker for cardiac disease [6], cardiac manifestations in HIV/AIDS and diabetic patients [7,8]. Since it is a novel area of research, further studies are required to confirm the clinical utility of CA2M in HIV patients.…”
Section: Introductionsupporting
confidence: 85%
“…Although acute phase proteins including α 2 M [46] have been established as markers of cardiac disease and dysfunction, nearly nothing is known about their function in adaptive responses to cardiac insults like cardiac hypertrophy or cardiac infarction. Systemic administration of rapamycin has been used successfully for the treatment of transplant rejection in clinical practice, and it has therefore been suggested to be a useful therapeutic means to suppress cardiac hypertrophy in patients [44].…”
Section: Discussionmentioning
confidence: 99%
“…In addition to this, gelsolin has been identified as being down-regulated by gel electrophoresis followed by MALDI-TOF/MS and tandem mass spectrometry. Alpha-2-macroglobulin, a protease inhibitor, has been associated with the progression of cardiac disease87. Peptidase inhibitor 16 (PI16), Ig mu heavy chain disease protein, and thyroid receptor-interacting protein 11, were not readily identified through literature searches as having a known role in cardiovascular disease.…”
Section: Resultsmentioning
confidence: 99%